 REDWOOD CITY, Calif.--BUSINESS WIRE--Guardant Health, Inc. Nasdaq: GH presents new data at the 2021 American Society of Clinical Oncology ASCO Annual Meeting being held from June 4-June 8, 2021, showing that its LUNAR-2 blood test is a highly sensitive test that can detect colorectal cancer CRC in early-stage cancer patients. This largest ever cohort continues to demonstrate the performance and robustness of the LUNAR-2 assay.1,2 Today, it is estimated that only 68 of adults, 50 years 